Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Biohaven Pharmaceutical Holding Company Ltd. BHVN
$13.50
-$0.31 (-2.32%)
На 18:00, 12 мая 2023
+74.07%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
926325696.00000000
-
week52high
20.57
-
week52low
5.54
-
Revenue
0
-
P/E TTM
-1
-
Beta
0.00000000
-
EPS
-12.39000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:50
Описание компании
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Piper Sandler | Neutral | Overweight | 19 авг 2022 г. |
| Wedbush | Neutral | Outperform | 08 авг 2022 г. |
| SVB Leerink | Market Perform | Outperform | 11 мая 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 11 мая 2022 г. |
| HC Wainwright & Co. | Neutral | Buy | 11 мая 2022 г. |
| Piper Sandler | Overweight | Overweight | 26 окт 2022 г. |
| Piper Sandler | Overweight | 12 окт 2022 г. | |
| BTIG | Buy | 02 дек 2022 г. | |
| JP Morgan | Overweight | 04 янв 2023 г. | |
| SVB Leerink | Outperform | 24 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Coric Vlad | A | 1543394 | 25800 | 31 окт 2022 г. |
| Coric Vlad | A | 109565 | 100000 | 28 окт 2022 г. |
| Coric Vlad | A | 1517594 | 41930 | 28 окт 2022 г. |
| Coric Vlad | A | 1475664 | 853380 | 25 окт 2022 г. |
| Buten Matthew | A | 166653 | 142857 | 25 окт 2022 г. |
| CHILDS JOHN W | A | 5691251 | 3900000 | 25 окт 2022 г. |
| Bailey Gregory | A | 1507971 | 200000 | 25 окт 2022 г. |
| GREGORY JULIA P | A | 25665 | 9523 | 25 окт 2022 г. |
| Coric Vlad | A | 399443 | 2100 | 05 окт 2022 г. |
| Coric Vlad | A | 397343 | 52523 | 05 окт 2022 г. |
Новостная лента
Is Biohaven Ltd. (BHVN) Stock Outpacing Its Medical Peers This Year?
Zacks Investment Research
30 мар 2023 г. в 11:23
Here is how Biohaven Ltd. (BHVN) and Hologic (HOLX) have performed compared to their sector so far this year.
Biohaven (BHVN) Acquires Dual Inhibitor for Brain Disorders
Zacks Investment Research
23 мар 2023 г. в 12:13
Biohaven (BHVN) has acquired an exclusive license for dual Inhibitor of TYK2/JAK1 for the pre-clinical study of immune-mediated brain disorders.
Biohaven: Spun And Done - Time To Exit
Seeking Alpha
09 мар 2023 г. в 17:06
Biohaven is on the far side of its spin cycle and faces the world as a much diminished company. Biohaven has upcoming catalysts, but they are either early stage or have serious question marks.
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
Investors Business Daily
02 февр 2023 г. в 12:52
Biohaven is taking the same tact that led to a nearly $12 billion Pfizer buyout with the rest of its pipeline — and BHVN stock has soared. The post Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric appeared first on Investor's Business Daily.
These Are the Top 10 Holdings of Paul Tudor Jones
24/7 Wall Street
10 янв 2023 г. в 22:55
Paul Tudor Jones is one of the most respected names in the hedge fund industry.